Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis.

Herein, we report a case of alopecia universalis and transient accommodation spasm presented after alemtuzumab administration in a patient previously treated with fingolimod. To the best of our knowledge, this is the first report of accommodation spasm as an acute adverse effect of alemtuzumab. Treatment with alemtuzumab in relapsing-remitting multiple sclerosis has been identified as a risk factor for developing secondary autoimmunity within the follow-up period (peak 18-36 months from the first infusion) such as thyroid disorders. This case highlights the need for postmarketing surveillance and the significance of reporting rare side effects related to alemtuzumab; its high efficacy should be weighted with potentially severe adverse events when making a therapeutic decision. Further studies in larger cohorts are needed to elucidate pathomechanisms of alemtuzumab.

Informations de copyright

© The Author(s), 2022.

Déclaration de conflit d'intérêts

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DT has received travel grants and consulting fees from Roche, Teva, Sanofi-Genzyme, Novartis, and Genesis Pharm. MB has received a research grant from the European Academy of Neurology (EAN) and travel grants from Merck, Teva, Novartis, Genesis Pharma, Pfizer and Sanofi-Genzyme. JST has received travel grants and fees for advisory boards from Sanofi-Genzyme, Genesis Pharma, Teva, Novartis, and Novartis. ME Evangelopoulos has received travel grants and consulting fees from Biogen, Roche, Teva, Genzyme, and Merk. CK has received grants and honoraria from Bayer, Biogen, Genesis Pharma, Merck-Serono, Novartis, Sanofi – Genzyme, and Teva. Authors AGV, GB, AD, IG, GS, LS: no disclosures.